

<p>Informazione Regolamentata n. 0957-36-2026</p>	<p>Data/Ora Inizio Diffusione 25 Marzo 2026 12:02:01</p>	<p>Euronext Milan</p>
---	--	-----------------------

Societa' : DIASORIN

Utenza - referente : DIASORINN01 - Ulisse Spada - Valerio Vaccarone

Tipologia : 3.1

Data/Ora Ricezione : 25 Marzo 2026 12:02:01

Data/Ora Inizio Diffusione : 25 Marzo 2026 12:02:01

Oggetto : Publication of the document for the Ordinary Shareholders' Meeting scheduled on April 29, 2026

*Testo del comunicato*

See in attachment.

## **DIASORIN: PUBLICATION OF THE DOCUMENTS FOR THE ORDINARY SHAREHOLDERS' MEETING SCHEDULED ON APRIL 29, 2026**

**Saluggia, March 25, 2026** – In relation to the ordinary shareholders' meeting of Diasorin S.p.A. (FTSE MIB: DIA) convened in a single call on April 29, 2026, at 3:00 p.m. CET, it is announced that - in compliance with the applicable legal requirements – today the Company made available at its registered office, on its website (<https://int.diasorin.com>, Section “Company/Governance/Shareholders’ Meeting/2026”) and on the on the authorized central storage mechanism “eMarketStorage” ([www.emarketstorage.com](http://www.emarketstorage.com)):

- The Report on the remuneration policy for 2026 and fees paid in 2025;
- the Explanatory Reports on the items on the agenda, including information documents drafted pursuant to art. 84-bis of Consob Regulation 11971/1999;
- the proxy forms pursuant section 125-*novies* and 135-*undecies* of Legislative Decree 58/1998.

The remaining documents related to the Shareholders’ Meeting will be made available within the terms and according to the modalities set forth by the law.

### **About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at [www.diasorin.com](http://www.diasorin.com)

### **FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**

#### **INVESTOR RELATIONS**

##### **Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

##### **Eugenia Ragazzo**

Corporate Investor Relations & ESG Senior Analyst  
[eugenia.ragazzo@diasorin.it](mailto:eugenia.ragazzo@diasorin.it)

Fine Comunicato n.0957-36-2026

Numero di Pagine: 3